


**Bisphenol A in Thermal Paper Receipts: Taylor et al. Respond**

http://dx.doi.org/10.1289/ehp.1104004R

We agree with Schwartz and Landrigan that there is a need for change in the regulatory system for chemicals used in products in the United States. Bisphenol A (BPA) is one of thousands of chemicals of concern, but it provides a striking example of what happens when there is no requirement for premarket testing. Full estrogenic activity was demonstrated for BPA when it was tested for use as a pharmaceutical drug in 1936, which should have precluded its use in the wide range of products that results in continuous exposure (Stahlhut et al. 2009). The findings we reported in our article (Taylor et al. 2011) show that clearance of BPA in mice, monkeys, and humans does not differ, and years of research has demonstrated that mice and rats are valid models for predicting the long-term adverse consequences of developmental exposure to estrogenic chemicals. A vast and rapidly growing number of studies with experimental animals (Richter et al. 2007) and humans (Braun and Hauser 2011) report adverse effects later in life as a result of exposure to BPA during development.

In the 2003–2004 National Health and Nutrition Examination Survey (NHANES) study, the Centers for Disease Control and Prevention estimated that 93% of people in the United States are exposed to BPA, with daily exposures being below “safe” levels. This conclusion is based on flawed studies using outdated approaches. We agree with Schwartz and Landrigan that we have to stop repeating the same mistakes made previously with chemicals such as lead, for which, after decades of repeatedly lowering “safe” exposure estimates, the current predicted “safe” level is still above levels now known to cause adverse effects. For endocrine-disrupting chemicals there are no threshold doses below which exposures are safe (Sheehan 2006), a reality that regulators are unwilling to acknowledge.

F.S.v.S. consulted for an attorney involved in civil litigation regarding the health effects of BPA, but he has no financial interests related to the sale or use of BPA. The remaining authors declare they have no actual or potential competing financial interests.

**Julia A. Taylor**

**Frederick S. vom Saal**

**Wade V. Welschons**

**Bertram Drury**

**George Rottinghaus**

University of Missouri

Columbia, Missouri

E-mail: TaylorJA@Missouri.edu

**Patricia A. Hunt**

School of Molecular Biosciences

Washington State University

Pullman, Washington

**Pierre-Louis Toutain**

**Céline M. Laffont**

INRA, TOXALIM (Research Centre in Food Toxicology) and Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse

Toulouse, France

**REFERENCES**


**Artificial Food Color Additives and Child Behavior**

http://dx.doi.org/10.1289/ehp.1104409

In his commentary, Weiss (2012) discusses results of the recent Food and Drug Administration (FDA) evaluation of the possible association between artificial food color additives (AFCs) and adverse behaviors in children, including those related to hyperactivity. The stated aim of the commentary is “to examine the basis of the FDA’s position, the elements of the review that led to its decision and that of the committee, and the reasons why this is an environmental issue.” In the commentary, however, a) the FDA’s petition review and safety assessment processes are misconstrued; b) the range of normal behaviors and the levels at which these behaviors can be considered adverse are not distinguished, and comparisons that cloud the distinction are unsupported; c) examples from individual studies are used out of context or irrespective of the conclusions expressed by the authors; d) specific results are cited from studies the FDA concluded were fundamentally flawed; and e) comprehensive reviews by other scientific panels are not mentioned. As a result, the viewpoint presented does not properly characterize the public health issue, the FDA’s evaluation and conclusions, or the processes involved, including the FDA’s proposed actions. This letter addresses as many general errors, omissions, and apparent flaws in the commentary as space permits.

In 2008, the Center for Science in the Public Interest (CSPI) petitioned the FDA to ban eight AFCs based primarily on results from clinical challenge studies on behavioral effects of these chemicals in children with a history of hyperactivity disorders or related behavioral problems (CSPI 2008). The petition also cited studies that tested potential...